gubra - Search News

AbbVie, Gubra and obesity

NewsNation on MSN · 16h

AbbVie enters into almost $2B contract with Gubra for obsesity drug

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

Crain's Chicago Business · 3d

AbbVie enters obesity drug market with Danish drugmaker

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.

MarketWatch · 3d

AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.

Seeking Alpha · 2d

AbbVie Steps Into The Ring In The Obesity Drug Wars

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.

Investor's Business Daily on MSN · 2d

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.

STAT · 3d

AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

BioPharma Dive2d

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Fierce Biotech3d

AbbVie pays Gubra $350M to make late play for obesity space

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

1don MSN

Healthy Returns: AbbVie is the newest potential weight loss drug market player

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...

PharmExec2d

AbbVie, Gubra Strike Deal to Develop Novel Weight Loss Treatment

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

BioSpace3d

Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie, Gubra announce license agreement to develop GUB014295

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the ...

2don MSN

AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Gubra A/S: Annual Report 2024: Excellent performance across Gubra

Gubra released its Annual Report for 2024. Significant progress was made in 2024 across several R&D projects, not the least by advancement of the anti-obesity Amylin program where positive topline ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results